Day One Biopharmaceuticals pany(DAWN) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In 2025, the company reported net product revenue of $155.4 million, representing a 172% year-over-year increase [6][35] - The fourth quarter net product revenue reached $52.8 million, reflecting a 37% sequential growth over Q3 [21][35] - The company ended 2025 with approximately $441 million in cash and no debt, providing a strong financial foundation [9][38] Business Line Data and Key Metrics Changes - OJEMDA remains the primary revenue driver, with over 4,600 total prescriptions in 2025, marking an increase of over 180% compared to 2024 [6][22] - The company achieved double-digit sequential quarterly growth throughout 2025, with Q4 prescriptions exceeding 1,300, representing an 11% growth quarter-over-quarter [21][22] Market Data and Key Metrics Changes - The company anticipates global expansion for OJEMDA, with regulatory approvals being prepared for ex-U.S. markets, including Europe [8] - Coverage rates for pediatric low-grade glioma (PLGG) remain above 95%, with over 90% of patients approved on the first request [24] Company Strategy and Development Direction - The company aims to solidify OJEMDA as the second-line standard of care in PLGG, with a focus on driving new patient starts and optimizing treatment persistence [23][25] - The acquisition of Mersana Therapeutics is seen as a strategic move to enhance the pipeline, particularly with the Emi-Le program targeting adenoid cystic carcinoma [39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2026, reiterating guidance for OJEMDA net product revenue of $225 million-$250 million [6][38] - The company is focused on establishing a strong scientific basis for OJEMDA's use in frontline settings through ongoing clinical trials [7][18] Other Important Information - The company reported a decline in total costs and operating expenses to $286 million for the full year 2025, down from $348 million in 2024 [36] - The company has maintained a favorable gross and net profile for OJEMDA, with gross and net margins expected to be in the range of 16%-19% in 2026 [38] Q&A Session Summary Question: How does the company maintain and improve persistency for OJEMDA? - Management highlighted that current persistency is robust, with a median duration of therapy trending towards 19 months, and identified opportunities to improve persistency through targeted physician education and patient support programs [45][47] Question: What are the expectations for the updated Emi-Le data? - Management indicated that substantial data will be shared mid-year, focusing on antitumor signals and safety datasets to support registration discussions with the FDA [52][56] Question: What are the early trends for 2026? - Management reiterated confidence in 2026 revenue guidance, noting strong demand in Q1, although specific quarterly details were not disclosed [61][63] Question: Can the company provide insights on treatment patterns for patients? - Management discussed the potential for treatment breaks and retreatment based on patient stability, emphasizing the importance of clinical decisions over radiographic assessments [78][80] Question: What is the expected response rate for Emi-Le in ACC? - Management stated that they aim for a robust dataset demonstrating significant efficacy and safety for Emi-Le, particularly in a population with urgent therapeutic needs [82][86]